News Sanofi's 'daughter of Dupixent' heads to phase 3 in asthma Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.
News AAD: Sanofi showcases data on possible Dupixent successor Sanofi says that its experimental drug amlitelimab has the potential to become a ‘best-in-class’ maintenance therapy for atopic dermatitis (AD) after reporting new phase 2
News Key drug in Sanofi's $1.45bn Kymab buyout shows promise in e... Already a major player in atopic dermatitis with Dupixent, Sanofi looked to expand its position in the category earlier this year when it
Digital AI-powered drug discovery is outpacing regulators, with Eric... During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
